Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials.

[1]  R. Giugliano,et al.  Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Journal of the American Heart Association.

[2]  Ž. Reiner.  Hypertriglyceridaemia and risk of coronary artery disease , 2017, Nature Reviews Cardiology.

[3]  I. Graham.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[4]  A. Guerrero,et al.  2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary , 2016, ASEAN heart journal : Official journal of the ASEAN Federation of Cardiology.

[5]  A. Sahebkar,et al.  Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. , 2016, Pharmacological research.

[6]  A. Sahebkar,et al.  The impact of statin therapy on plasma levels of von Willebrand factor antigen , 2015, Thrombosis and Haemostasis.

[7]  Y. Panahi,et al.  Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. , 2015, Clinical nutrition.

[8]  G. Norata,et al.  Apolipoprotein C-III: From Pathophysiology to Pharmacology. , 2015, Trends in pharmacological sciences.

[9]  J. Zamorano,et al.  A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. , 2015, Atherosclerosis. Supplements.

[10]  A. Sahebkar,et al.  Association between statin use and plasma D-dimer levels , 2015, Thrombosis and Haemostasis.

[11]  M. Banach,et al.  Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. , 2015, Atherosclerosis.

[12]  Ž. Reiner.  Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease? , 2015, Cardiology.

[13]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[14]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[15]  F. Sacks,et al.  Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case–Control Study in 13 Countries , 2013, Circulation.

[16]  Ž. Reiner.  Statins in the primary prevention of cardiovascular disease , 2013, Nature Reviews Cardiology.

[17]  Richard G. Lee,et al.  Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.

[18]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[19]  W. Weintraub,et al.  Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. , 2012, Atherosclerosis.

[20]  E. Rimm,et al.  Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease , 2011, Circulation.

[21]  W. März,et al.  "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. , 2011, Current vascular pharmacology.

[22]  W. März,et al.  "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. , 2011, Current vascular pharmacology.

[23]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[24]  H. Ginsberg,et al.  Apolipoprotein CIII: 42 years old and even more interesting. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[25]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[26]  G. Watts,et al.  Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. , 2010, The American journal of clinical nutrition.

[27]  Ž. Reiner.  Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & clinical pharmacology.

[28]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[29]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[30]  F. Sacks,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients , 2008, Diabetes & vascular disease research.

[31]  G. Watts,et al.  Dose-Dependent Effect of Rosuvastatin on VLDL–Apolipoprotein C-III Kinetics in the Metabolic Syndrome , 2008, Diabetes Care.

[32]  D. Mikhailidis,et al.  Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study , 2008 .

[33]  C. Ballantyne,et al.  Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy , 2007, Current medical research and opinion.

[34]  P. Libby,et al.  Apolipoprotein CIII Induces Expression of Vascular Cell Adhesion Molecule-1 in Vascular Endothelial Cells and Increases Adhesion of Monocytic Cells , 2006, Circulation.

[35]  E. Sijbrands,et al.  Plasma apolipoprotein A5 and triglycerides in type 2 diabetes , 2006, Diabetologia.

[36]  P. Libby,et al.  Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells , 2006, Circulation.

[37]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[38]  J. Xu,et al.  Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. , 2004, The Journal of clinical investigation.

[39]  B. Patterson,et al.  Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. , 2004, The Journal of clinical endocrinology and metabolism.

[40]  Nancy Dekki,et al.  Apolipoprotein CIII promotes Ca2+-dependent β cell death in type 1 diabetes , 2004 .

[41]  E. Trabetti,et al.  Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease Published, JLR Papers in Press, October 16, 2003. DOI 10.1194/jlr.M300253-JLR200 , 2003, Journal of Lipid Research.

[42]  G. Assmann,et al.  Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. , 2003, Atherosclerosis.

[43]  F. Sacks,et al.  LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[44]  G. Watts,et al.  Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. , 2003, Diabetes.

[45]  F. Sacks,et al.  Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. , 2001, Journal of lipid research.

[46]  B. Staels,et al.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. , 2001, The Journal of clinical investigation.

[47]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[48]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[49]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[50]  J. Auwerx,et al.  3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase , 1999, FEBS letters.

[51]  W. Mack,et al.  The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[52]  D. Arveiler,et al.  Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. , 1996, Journal of lipid research.

[53]  T. Leff,et al.  Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. , 1995, Journal of lipid research.

[54]  L. Labree,et al.  Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[55]  J. Breslow,et al.  Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. , 1994, Journal of lipid research.

[56]  S. Azen,et al.  Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin , 1994, Circulation.

[57]  J. Fruchart,et al.  Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. , 1990, Atherosclerosis.

[58]  C. Ehnholm,et al.  Effect of serum and C‐apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase , 1976, FEBS letters.

[59]  M. Johnston,et al.  M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT , 2014 .

[60]  M. Taskinen,et al.  ESC/EAS Guidelines for the Management of Dyslipidaemias , 2013 .

[61]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[62]  D. Mikhailidis,et al.  Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. , 2008, Current medical research and opinion.

[63]  G. Page,et al.  Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. , 2005, Journal of diabetes and its complications.

[64]  H. Jörnvall,et al.  Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.